The maximum tolerated dose of Adalimumab has not been established in humans. No dose-limiting toxicities have been observed during clinical trials with Adalimumab. Multiple doses up to 10 mg/kg have been administered to patients in clinical trials without evidence of dose-limiting toxicities. In case of overdosage, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions or effects and appropriate symptomatic treatment instituted immediately.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
